0steoporosis Therapeutic and Diagnostic Markets Rise into Next Decade

The osteoporosis therapeutic and diagnostic markets are comprised of many players, each vying to develop differentiated products in a competitive but prosperous market. So prosperous that in 2000, worldwide therapeutic sales are projected to be $5.5 billion and worldwide diagnostic sales are estimated to reach $396.6 million. Growth will be driven by an expected worldwide patient population of 220 million and the introduction of several hopeful blockbuster products, according to a new study published by Front Line Strategic Management Consulting, Inc.

Osteoporosis treatment at this time relies primarily on hormone replacement due to its high efficacy and low cost. This class currently holds 69% of the market and is expected to capture 63% in 2005. Wyeth-Ayerst will hold a commanding market share in 1998 due to the success of Premarin. However, this share is expected to shrink by 2005 as Eli Lilly's Evista, Merck's Fosamax, and Procter & Gamble's Actonel become leading products.

Front Line Strategic Management Consulting, Inc., is a strategy and market consultancy specializing in the pharmaceutical and biotechnology industries, providing clients with technology and market evaluations, strategic and tactical recommendations and business opportunity assessments.

For more information contact: Troy Franey, Front Line Strategic Management Consulting, Inc., 1065 E. Hillsdale Blvd, Suite 403, Foster City, CA 94404.Tel: 650-525-2982, Fax: 650-525-2727.